US 11,884,645 B2
Sulfonyl acetamides as NLRP3 inhibitors
David Miller, Cambridge (GB); Jimmy Van Wiltenburg, Groningen (NL); and Matthew Cooper, Cambridge (GB)
Assigned to INFLAZOME LIMITED, Dublin (IE)
Appl. No. 16/977,452
Filed by Inflazome Limited, Dublin (IE)
PCT Filed Mar. 1, 2019, PCT No. PCT/EP2019/055144
§ 371(c)(1), (2) Date Sep. 1, 2020,
PCT Pub. No. WO2019/166628, PCT Pub. Date Sep. 6, 2019.
Claims priority of application No. 1803412 (GB), filed on Mar. 2, 2018; and application No. 1902319 (GB), filed on Feb. 20, 2019.
Prior Publication US 2020/0399243 A1, Dec. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/12 (2006.01); C07D 231/18 (2006.01)
CPC C07D 401/12 (2013.01) [C07D 231/18 (2013.01)] 20 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Q is selected from 0 or S;
R1 is a 5-membered heteroaryl group, wherein the 5-membered ring structure consists of one or more carbon atoms, one or more nitrogen atoms and optionally one or more oxygen atoms, wherein R1 is substituted with R6 and R1 may optionally be further substituted;
R2 is a cyclic group substituted at the α and α′ positions, wherein R2 may optionally be further substituted;
R3 is hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2;
R4 is hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or
R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated cyclic group, wherein the cyclic group may optionally be substituted;
R5 is independently an optionally substituted C1-C4 alkyl group; and
R6 is any group comprising a nitrogen atom;
provided the compound is not

OG Complex Work Unit Chemistry